CYCC News and Press, Cyclacel Pharmaceuticals Inc. From 08/10/22

- Oral fadraciclib demonstrated good tolerability with continuous dosing; anticipate entering Phase 2 POC stage in 2H 2022 – - Demonstrated evidence of target engagement for CDK2 and CDK9 – - Company to host R&D day in ...

Cyclacel Pharmaceuticals ( NASDAQ: CYCC ) is scheduled to announce Q2 earnings results on Tuesday, August 9th, after market close. The consensus EPS Estimate is -$0.67 Over the last 3 months, EPS estimates have seen 3 upward revisions and 0 downward. For furt...

Cyclacel Pharmaceuticals is an oncology company with two major value drivers in Phase 1/2 trials and overdue catalysts. It trades at an $11 million market cap, with last reported cash of $34.5 million, and mean analyst estimate shows a +1,500% rise potential. Oral fadraciclib, an ...

BERKELEY HEIGHTS, N.J., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce second quarter 2022 financial results ...

Gainers: SIGA Technologies SIGA +20% . Tonix Pharmaceuticals TNXP +16% . Chimerix CMRX +13% . Galectin Therapeutics ( GALT ) +7% . Verona Pharma ( VRNA ) +3% . Losers: Enveric Biosciences ( ENVB ) -23% . Koninkli...

Gainers: 1Life Healthcare ONEM +67% . Tabula Rasa HealthCare ( TRHC ) +27% . Cano Health ( CANO ) +15% . Repligen ( RGEN ) +15% . Oak Street Health ( OSH ) +10% . Losers: LumiraDx LMDX -25% . Verve Therapeuti...

What Are Penny Stocks? Penny stocks are shares of companies trading for less than $5 per share. Some traders will have definitions of penny stocks , including stocks trading for $0.99 or less. No matter how they’re defined, it comes secondary to the reason for wondering what ...

Gainers: NeuroSense Therapeutics ( NRSN ) +53% . Rapid Micro Biosystems ( RPID ) +36% . Burning Rock Biotech ( BNR ) +15% . Tyra Biosciences ( TYRA ) +7% . Addex Therapeutics ( ADXN ) +5% . Losers: Renalytix ( RNLX ) -40% ...

- Completed Enrollment in Phase 1 Dose Escalation with Oral Fadraciclib in Solid Tumors - - No Dose Limiting Toxicities Observed at All Dose Levels Enrolled to Date - - Demonstrated Evidence of Target Engagement for CDK2 and CDK9 - - Early Anticancer Activity...

BERKELEY HEIGHTS, N.J., June 22, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the election of Kenneth M....